Cover Image

Update breast cancer 2018 (Part 1) - primary breast cancer and biomarkers

<p>This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association...

Full description

Saved in:
Bibliographic Details
Main Authors: Ţăran, Florin-Andrei (Author) , Schneeweiss, Andreas (Author) , Wallwiener, Markus (Author) , Schütz, Florian (Author)
Format: Article (Journal)
Language:English
Published: 21. März 2018
In: Geburtshilfe und Frauenheilkunde
Year: 2018, Volume: 78, Issue: 03, Pages: 237-245
ISSN:1438-8804
DOI:10.1055/s-0044-101613
Online Access:Verlag, Volltext: https://doi.org/10.1055/s-0044-101613
Verlag, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-101613
Get full text
Author Notes:Florin-Andrei Taran, Andreas Schneeweiss, Michael P. Lux, Wolfgang Janni, Andreas D. Hartkopf, Naiba Nabieva, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Achim Wöckel, Johannes Ettl, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Diethelm Wallwiener, Sara Y. Brucker, Peter A. Fasching, Tanja N. Fehm, Florian Schütz
Description
Summary:<p>This summary provides an overview of how new therapies or new aspects of established therapies relate to the latest findings. Neoadjuvant therapy, local therapy, new aspects of systemic therapy, and prognostic and predictive factors are presented. In the neoadjuvant setting, the association between pathological complete response (pCR) and prognosis is still of interest as is the identification of new molecular predictors for new therapies such as CDK4/6 inhibitors. As regards surgical treatment, the target is still to reduce the aggressiveness of surgery. To achieve this, a better understanding particularly of ductal carcinoma in situ is required. With regard to systemic therapy, more data on the best combinations and therapy sequences for existing therapies is available. Finally, the use of prognostic and predictive factors may help to avoid overtreatment and ensure that patients only receive therapies which have been shown to be effective for their specific condition and have fewer side effects.</p>
Item Description:Gesehen am 09.05.2019
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/s-0044-101613

Similar Items